MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Baseline predictors of clinical and imaging progression in Parkinson’s disease: Results from the PPMI study

L. Chahine, A. Siderowf, C. Caspell-Garcia, J. Barnes, N. Seedorff, C. Coffey, D. Galasko, B. Mollenhauer, V. Arnedo, N. Daegele, M. Frasier, C. Tanner, K. Kieburtz, K. Marek (Pittsburgh, PA, USA)

Meeting: 2018 International Congress

Abstract Number: 842

Keywords: Parkinsonism

Session Information

Date: Sunday, October 7, 2018

Session Title: Other

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To identify clinical, imaging, and biochemical measures, obtained early in the disease course that predict clinical and dopamine transporter (DAT) imaging progression in PD.

Background: Improved prognostic information in PD would be useful both clinically and in research. Baseline characteristics that are associated with disease progression could be used to select study participants, making possible smaller and/or shorter clinical trials.

Methods: Data from the Parkinson’s Progression Markers Initiative (PPMI) study were used for this analysis. At enrollment, PPMI participants had disease duration ≤2 years, abnormal DAT SPECT, and were untreated with PD medications. Linear mixed-effects models were used to identify predictors of change in MDS-UPDRS total score. Baseline predictors included clinical (motor scales, non-motor questionnaires, orthostatic systolic blood pressure (SBP), BMI), CSF (abeta1-42, alpha-synuclein, total tau, phospho-tau), and DAT SPECT binding measures (mean putamen, mean striatum). Analyses were adjusted for sex and baseline values for age, MDS-UPDRS score, and disease duration.

Results: Among 423 PD participants enrolled in PPMI (mean age 61.7 years, 65.48% male, mean disease duration 6.71 months), mean follow-up duration was 4.25 years. Predictors of change in MDS-UPDRS total score included: male gender (β=1.903; 95%CI 0.069,3.738; p=0.042), orthostatic SBP change (β =-0.076; 95% CI -0.144,-0.008; p=0.030), CSF abeta1-42 (β=-0.003 (95% CI -0.006,-0.001; p=0.021), and mean putamen DAT binding (β=-4.828; 95% CI -7.950,-1.707; p=0.003). Predictors of change in mean striatum DAT binding included: modified Schwab and England (β=0.071; 95% CI 0.004, 0.480; p=0.242), RBD symptoms (β=-1.003; 95%CI -1.527, -0.479; p=0.0002) and orthostatic SBP (β=0.115; 95%CI 0.007, 0.224; p=0.036).

Conclusions: In the PPMI PD cohort, several baseline demographic and clinical variables were associated with greater progression of MDS-UPDRS. Among biomarkers, significant associations were identified between mean putamen DAT binding and CSF abeta1-42 and change in MDS-UPDRS. A few motor and non-motor clinical features were associated with reduced DAT binding over time. While these factors may help stratify patients for clinical trial participation, discovery of novel markers with greater predictive capacity is still needed to optimize trial efficiency.

To cite this abstract in AMA style:

L. Chahine, A. Siderowf, C. Caspell-Garcia, J. Barnes, N. Seedorff, C. Coffey, D. Galasko, B. Mollenhauer, V. Arnedo, N. Daegele, M. Frasier, C. Tanner, K. Kieburtz, K. Marek. Baseline predictors of clinical and imaging progression in Parkinson’s disease: Results from the PPMI study [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/baseline-predictors-of-clinical-and-imaging-progression-in-parkinsons-disease-results-from-the-ppmi-study/. Accessed May 19, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/baseline-predictors-of-clinical-and-imaging-progression-in-parkinsons-disease-results-from-the-ppmi-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley